Through the development of an integrated infrastructure with a strong focus on biomedical research we have become much more than a traditional biobank. In order to serve the needs of our partners and clients optimally, we have set up two axes of priority research: biospecimen research and personalised medicine.
Biospecimen research studies the biological samples themselves and the best ways to collect, process, analyse and store them. Led and carried out by our Biorefinery department, biospecimen research is one of the most important factors in our commitment to continuously improve the quality of our samples and services. In addition, the results, which are published in peer-reviewed journals or as guidelines, serve the international biomedical research and biobanking community.
We are firmly invested in supporting research that will advance the introduction of personalised medicine for the benefit of patients and we have decided to make cancer, diabetes, the general population, microbiome, Parkinson’s disease and biospecimen research a priority. Most of our national projects are run under the umbrella of the Personalised Medicine Consortium (PMC). Led by a principle investigator from a research institute or hospital, these projects focus on investigating disease mechanisms, diagnostics, or novel treatments. We function as a bridge between clinicians and researchers by contributing our comprehensive services to these projects.